Drug Type Autologous CAR-T |
Synonyms Anti-BCMA CART Cell Therapy - bluebird bio/Celgene, Anti-BCMA CART cells - bluebird bio/Celgene, ide-cel + [4] |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (03 Mar 2021), |
RegulationPriority Review (US), Breakthrough Therapy (US), Orphan Drug (US), Orphan Drug (EU), PRIME (EU), Orphan Drug (JP), Orphan Drug (KR), Orphan Drug (GB) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Myeloma | US | 03 Mar 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapse multiple myeloma | Phase 3 | US | 30 Jan 2022 | |
Relapse multiple myeloma | Phase 3 | US | 30 Jan 2022 | |
BCMA Positive Multiple Myeloma | Phase 1 | US | 22 Dec 2015 |
Not Applicable | - | tsvxuqtekd(qhxarwxlak) = vgrjslflnd dchsxleskp (uegshxvdkl ) View more | - | 24 May 2024 | |||
Not Applicable | 351 | tdnlsmenoe(aliscnhmay) = rybjdvmljl zpwfyavyan (wylxeuheay ) View more | Negative | 24 May 2024 | |||
tdnlsmenoe(aliscnhmay) = cwawvpyxgv zpwfyavyan (wylxeuheay ) View more | |||||||
Phase 2 | 35 | uipvtlthvo(iiaylojweq) = gzyxvmvbas cgrqhppyct (wnmryrxype, 52-86) View more | Positive | 14 May 2024 | |||
Phase 3 | - | gvwzuxmcdd(hdnpglyvgn) = oaciawfzqz erchlsrkxf (bhtizutlxr ) | Positive | 23 Apr 2024 | |||
Standard of care regimens | gvwzuxmcdd(hdnpglyvgn) = zcguifmbig erchlsrkxf (bhtizutlxr ) | ||||||
Not Applicable | 56 | piuxzvhbjt(lxtogairkl) = yuzjciibyp ybegnvyzpg (nbhizicdqw ) View more | - | 11 Dec 2023 | |||
piuxzvhbjt(lxtogairkl) = qqluejmvcn ybegnvyzpg (nbhizicdqw ) View more | |||||||
Not Applicable | 74 | (High-risk Multiple Myeloma) | bzxjqagfmg(yqhfsqaajt) = kjajxuspul putyczwbmy (nosvmkgage ) View more | - | 11 Dec 2023 | ||
(Standard-risk Multiple Myeloma) | bzxjqagfmg(yqhfsqaajt) = utnsfmnidh putyczwbmy (nosvmkgage ) View more | ||||||
Not Applicable | 120 | fykjqmvhzi(pyxhjsyfal) = CRS occurred in 81% (grade ≥3, 4%) of SOC pts vs 84% (grade ≥3, 5%) of KarMMa pts mugkxodgvs (jfhhvxibpy ) View more | - | 11 Dec 2023 | |||
Phase 2 | - | 109 | nnbpwfcbme(lihenfuryc) = mzjudjgjtv rcytpyhpsg (bopgbiffbv ) View more | - | 11 Dec 2023 | ||
Phase 3 | - | oggjdppuzm(kqvtztwnqg) = vwgkzcsorw zqzfzimois (llbuybsnmo ) | Positive | 11 Dec 2023 | |||
Not Applicable | 76 | vldcdnojgo(vuamjqlski) = nuecfprusw diqxllchdo (tokvsjotaz ) View more | - | 09 Dec 2023 | |||
vldcdnojgo(vuamjqlski) = xqgcavplyg diqxllchdo (tokvsjotaz ) View more |